Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tangning Tongluo
- Development stage
- Phase 3
- Lead developer
- Beletalent Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tangning Tongluo (TNTL) is a Class 1.1 traditional Chinese Miao medicine developed by Beletalent (Zhuhai) Pharmaceutical Co., Ltd., a subsidiary of Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. It is a multi-component herbal formulation composed of four ingredients: kewoluoqu, Herba Plantaginis, Herba Agrimoniae, and Flos Lonicerae. The drug is primarily indicated for the treatment of non-proliferative diabetic retinopathy (NPDR). Its mechanism of action involves improving retinal microcirculation, reducing microcirculatory stasis, and reversing pathological changes in retinal blood vessels. Originally developed as an in-hospital preparation in 2014, it has an extensive clinical history. In November 2024, it became the first drug in China to receive approval from the National Medical Products Administration (NMPA) to proceed directly to Phase III clinical trials, bypassing Phase II trials based on its established clinical efficacy and safety profile.
- Brand names
- Tangningtongluo Tablet
- Other names
- Tangning Tongluo Tablets
02
Targets
Macrophage inflammatory protein-1 gamma/C-C chemokine receptor type 1 axis
Beyond the preview
Go deeper on Tangning Tongluo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tangning Tongluo.